Toshifusa Nakajima
Overview
Explore the profile of Toshifusa Nakajima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, et al.
Radiother Oncol
. 2019 Apr;
134:199-203.
PMID: 31005216
Purpose: The study was designed to evaluate the safety and efficacy of adding oxaliplatin to py (CRT) with S-1 in patients with locally advanced rectal carcinoma (LARC). We report here...
2.
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, et al.
Gastric Cancer
. 2017 Dec;
21(3):428.
PMID: 29234896
The correct name of the twelfth author should be ''Yasuhiro Yuasa", and not ''Yasuhiko Yuasa'' as given in the original publication of the article.
3.
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, et al.
Gastric Cancer
. 2017 Sep;
21(3):421-427.
PMID: 28936560
Background: S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for...
4.
Honda M, Wong S, Healy M, Nakajima T, Watanabe M, Fukuma S, et al.
J Cancer
. 2017 Aug;
8(11):1935-1942.
PMID: 28819392
The incidence and characteristics of gastric cancer have been shown to vary widely across Western and Eastern countries. Our study had two aims: to evaluate long-term trends in gastric adenocarcinoma...
5.
Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, et al.
Clin Colorectal Cancer
. 2016 Nov;
16(3):e171-e180.
PMID: 27856123
Introduction: Primary tumor location is a critical prognostic factor in metastatic colorectal cancer (mCRC); however, it remains unclear whether tumor location is a predictor of the response to cetuximab treatment....
6.
Tsuji A, Sunakawa Y, Ichikawa W, Nakamura M, Kochi M, Denda T, et al.
Target Oncol
. 2016 Jun;
11(6):799-806.
PMID: 27306648
Background: Retrospective studies have found that early tumor shrinkage (ETS) and depth of response (DpR) are associated with favorable outcomes in patients with metastatic colorectal cancer (mCRC); however, few prospective...
7.
Nakajima T
Gan To Kagaku Ryoho
. 2016 May;
43(4):486-9.
PMID: 27220801
Investigator-oriented post-marketing clinical trials of anti-cancer agents are faced to financial crisis due to drastic decrease in research-funds from pharmaceutical companies caused by a scandal in 2013. In order to...
8.
Sunakawa Y, Yang D, Moran M, Astrow S, Tsuji A, Stephens C, et al.
Cancer Biol Ther
. 2016 Apr;
17(7):751-9.
PMID: 27104867
Several studies have reported that epidermal growth factor receptor (EGFR)-related molecules may serve as predictors of cetuximab treatment for metastatic colorectal cancer (mCRC), such as EGFR gene copy number (GCN),...
9.
Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, et al.
Gastric Cancer
. 2015 Sep;
19(2):350-360.
PMID: 26385385
Background: Although postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, has become a standard of care for gastric cancer in Japan, nonresponders may suffer from the cost and adverse reactions...
10.
Matsusaka S, Ishihara S, Kondo K, Horie H, Uehara K, Oguchi M, et al.
Radiother Oncol
. 2015 Sep;
116(2):209-13.
PMID: 26337743
Purpose: This study was designed to evaluate the safety and efficacy of adding oxaliplatin to preoperative chemoradiotherapy (CRT) with S-1 in patients with locally advanced rectal carcinoma (LARC). Patients And...